ArticleCureus2026
Focal Hepatic Steatosis Mimicking a Hilar Tumor With Rapid Resolution After Glycemic Control: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal hepatic steatosis can present as a mass-like pseudolesion, particularly in segment IV (S4) adjacent to the hepatic hilum, and may raise concern for perihilar malignancy. We report a 56-year-old woman with severe hyperglycemia (random plasma glucose 564 mg/dL; HbA1c 12.4%) in whom ultrasonography and computed tomography revealed a small hilar S4 lesion suspicious for a perihilar tumor. Magnetic resonance imaging demonstrated a prominent signal drop on opposed-phase chemical shift imaging without diffusion restriction and without biliary ductal abnormality on MR cholangiopancreatography, favoring focal steatosis rather than neoplasm. Based on these findings, we prioritized metabolic optimization with short-interval follow-up rather than immediate biopsy. After intensive glycemic control, HbA1c improved to 6.6%, and the lesion completely disappeared within three months, confirmed sequentially on ultrasonography, contrast-enhanced CT, and MRI. This case highlights a practical strategy: when chemical shift MRI supports focal steatosis and ancillary malignant features are absent, metabolic optimization followed by short-interval follow-up imaging can confirm the diagnosis and avoid unnecessary invasive procedures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.